RECOMBINANT VACCINE MARKET ANALYSIS

A recombinant vaccine is a vaccine produced through recombinant deoxyribonucleic acid (DNA) technology. The gene that creates the protein for a bacteria or virus is isolated and placed inside another cell’s genes. When that cell reproduces, it produces vaccine proteins that mean the immune system will recognize the protein and protect the body against the bacteria or virus

Global recombinant vaccines market is estimated to be valued at US$ 1,116.1 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Figure 1.Global Recombinant Vaccines Market Share (%), by Disease Type, 2022

To learn more about this report, request sample copy

Increasing incidence of zoonotic diseases and emerging technologies for developing vaccines are expected to drive growth of the recombinant vaccines market

Increasing incidence of zoonotic diseases and emerging technologies for developing vaccines are expected to drive growth of the recombinant vaccines market. For instance, according to the data provided by Centers for Disease Control and Prevention report 2022, a total of 4,702 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2021, and May 28, 2022 in the U.S.

Figure 2.Global Recombinant Vaccines Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Increasing investments and research and development activities for the development of new vaccines are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in market for developing recombinant vaccines is expected to drive the market growth over the forecast period. For instance, in February 2021, Sanofi, a multinational healthcare company, and GSK plc., a multinational pharmaceutical company, announced the initiation of a new phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate

Global Recombinant Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, vaccines and medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regards to the transportation of drugs, vaccines and medical devices from one place to another.

However, the COVID-19 pandemic had a positive impact on the global recombinant vaccines market, owing to the increased research and development activities by the key players for developing recombinant and other vaccines for the COVID-19 infection. The key players in market were focused on developing and receiving approvals for recombinant vaccines to treat COVID-19 infection. For instance, in June 5, 2022, the Drugs Controller General of India gave approval to Biological E Limited., an India-based biotechnology and biopharmaceutical company, for the Corbevax vaccine to be administered as a booster shot to individuals aged 18 years and above, six months after they have already received two doses of either Serum Institute’s Covishield or Bharat Biotech’s Covaxin. Corbevax is a recombinant protein sub-unit vaccine developed against COVID-19 infection.

Global Recombinant Vaccines Market: Key Developments

In June 1, 2022, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,345,896 to the company on May 31, 2022. This patent, entitled ‘Synthetic Chimeric Poxviruses’, which include claims covering synthetic horsepox virus, the basis for the company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the company’s recombinant pox virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.

In June 1, 2022, VBI Vaccines Inc., a biopharmaceutical company, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had granted marketing authorization for PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)] for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Global Recombinant Vaccines Market: Restraint

The major factors that would hinder growth of the global recombinant vaccines market are, high cost of vaccines, low  immunogenicity and the need for repeated vaccination. For instance, according to the Centers for Disease Control and Prevention vaccine price lists 2022, the private sector price of Gardasil, recombinant human papillomavirus vaccine, was around US$ 253.60.

Key Players

Major players operating in the global recombinant vaccines market include Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma